Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Claudin18.2 CAR-T in advanced solid tumors
NCT07266311Phase 1Not yet recruiting
- Sponsor
- Ucello Biotechnology
- Start
- Dec 2025
- Primary completion
- Dec 2035
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Claudin18.2 CAR-T in solid tumor, sponsored by Ucello Biotechnology. Primary endpoint: CAR-T-related adverse events at 3 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
Claudin18.2 CAR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07266311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266311.